Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RGEN
stocks logo

RGEN

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
174.77M
+13.43%
0.394
+19.25%
175.16M
+13.1%
0.398
-7.37%
190.90M
+13.94%
0.491
+11.6%
Estimates Revision
The market is revising Upward the revenue expectations for Repligen Corporation (RGEN) for FY2025, with the revenue forecasts being adjusted by 1.37% over the past three months. During the same period, the stock price has changed by -7.82%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.37%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-1.85%
In Past 3 Month
Stock Price
Go Down
down Image
-7.82%
In Past 3 Month
15 Analyst Rating
up Image0
Wall Street analysts forecast RGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGEN is 181.25 USD with a low forecast of 150.00 USD and a high forecast of 207.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
5 Hold
0 Sell
Moderate Buy
up Image0
Current: 131.300
sliders
Low
150.00
Averages
181.25
High
207.00
up Image0
Current: 131.300
sliders
Low
150.00
Averages
181.25
High
207.00
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$180
2025-05-05
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$180
2025-05-05
Reiterates
Strong Buy
Reason
RBC Capital
Conor McNamara
Buy
Maintains
$202 → $189
2025-04-30
Reason
RBC Capital
Conor McNamara
Price Target
$202 → $189
2025-04-30
Maintains
Buy
Reason
RBC Capital lowered the firm's price target on Repligen to $189 from $202 but keeps an Outperform rating on the shares after its Q1 results. The company's post-pandemic rebound remains on track, with minimal exposure to macro and U.S. policy headwinds faced by the rest of the Life Science Tools sector, the analyst tells investors in a research note. RBC adds however that its price target cut is due to market multiple compression.
JP Morgan
Rachel Vatnsdal
Buy
Maintains
$200 → $190
2025-04-29
Reason
JP Morgan
Rachel Vatnsdal
Price Target
$200 → $190
2025-04-29
Maintains
Buy
Reason
JPMorgan analyst Rachel Vatnsdal lowered the firm's price target on Repligen to $190 from $200 and keeps an Overweight rating on the shares after the company reported a "strong top-line and bottom-line 1Q beat" while reiterating organic revenue growth guidance for the year. The firm "applauds" the company's consistent performance during the bioprocessing recovery and continues to believe that Repligen's portfolio positions it as "a best-in-class bioprocessing pure play," the analyst tells investors.
Canaccord Genuity
Kyle Mikson
Hold
Maintains
$170 → $150
2025-04-16
Reason
Canaccord Genuity
Kyle Mikson
Price Target
$170 → $150
2025-04-16
Maintains
Hold
Reason
Canaccord analyst Kyle Mikson lowered the firm's price target on Repligen to $150 from $170 and keeps a Hold rating on the shares.
Evercore ISI Group
Daniel Markowitz
Hold
Initiates
$155
2025-03-18
Reason
Evercore ISI Group
Daniel Markowitz
Price Target
$155
2025-03-18
Initiates
Hold
Reason
Evercore ISI initiated coverage of Repligen with an In Line rating and $155 price target. The firm sees the company as a high quality pure play bioprocess supplier with $649M of revenue and a market cap of about $8B, the analyst tells investors in a research note. After two consecutive years of organic declines, Repligen looks positioned to benefit from market recovery and continue to grow more than 500-1000 bps above market growth rate amid outperformance driven by differentiated products and higher clinical mix, the firm added.
JP Morgan
Rachel Vatnsdal
Buy
Maintains
$190 → $200
2025-02-21
Reason
JP Morgan
Rachel Vatnsdal
Price Target
$190 → $200
2025-02-21
Maintains
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Repligen Corp (RGEN.O) is 74.95, compared to its 5-year average forward P/E of 88.59. For a more detailed relative valuation and DCF analysis to assess Repligen Corp 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
88.59
Current PE
74.95
Overvalued PE
110.12
Undervalued PE
67.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
59.20
Current EV/EBITDA
50.00
Overvalued EV/EBITDA
74.13
Undervalued EV/EBITDA
44.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
15.10
Current PS
9.82
Overvalued PS
18.72
Undervalued PS
11.48

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 135.49% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

RGEN News & Events

Events Timeline

(ET)
2025-04-29
07:36:57
Repligen sees FY25 adjusted EPS $1.63-$1.72, consensus $1.71
select
2025-04-29
07:36:14
Repligen reports Q1 adjusted EPS 39c, consensus 35c
select
2025-04-08 (ET)
2025-04-08
07:36:09
Repligen appoints Jacob Johnson as VP, investor relations
select
Sign Up For More Events
Sign Up For More Events

News

Preview
9.0
05-30TipRanks
Regeneron Stock (REGN) Retreats as Lung Disease Drug Data Disappoints

  • Stock Performance: Shares of Regeneron and Sanofi fell significantly after mixed results from their lung disease treatment Itepekimab, with Regeneron dropping 10% and Sanofi 5% in pre-market trading.

  • Trial Results: While one phase 3 trial showed a positive outcome for former smokers with COPD, the second trial did not meet its primary endpoint, prompting further investigation into the drug's efficacy and future regulatory steps.

Preview
2.0
05-27Newsfilter
Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report

  • Corporate Sustainability Report Release: Repligen Corporation has published its 2024 Corporate Sustainability Report, highlighting progress in sustainability across six key areas and aligning with UN SDGs and reporting frameworks like GRI and SASB.

  • Sustainability Achievements: The company achieved a transition to 100% renewable electricity at all manufacturing sites, reduced waste generation by 25%, and expanded its Scope 3 emissions inventory, while also completing a program to integrate human rights principles into its operations.

Preview
6.5
05-22NASDAQ.COM
The Math Shows MDY Can Go To $634

  • ETF Analyst Target Prices: The SPDR S&P MIDCAP 400 ETF Trust (MDY) has an implied analyst target price of $633.71, indicating a potential upside of 16.02% from its current trading price of $546.20.

  • Individual Stock Upside Potential: Notable underlying holdings such as Onto Innovation Inc, Roivant Sciences Ltd, and Repligen Corp show significant upside potential, with expected increases of 60.77%, 54.67%, and 54.51% respectively based on average analyst target prices.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Repligen Corp (RGEN) stock price today?

The current price of RGEN is 131.3 USD — it has decreased -0.53 % in the last trading day.

arrow icon

What is Repligen Corp (RGEN)'s business?

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Company’s chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Company’s TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.

arrow icon

What is the price predicton of RGEN Stock?

Wall Street analysts forecast RGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGEN is 181.25 USD with a low forecast of 150.00 USD and a high forecast of 207.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Repligen Corp (RGEN)'s revenue for the last quarter?

Repligen Corp revenue for the last quarter amounts to 169.17M USD, increased 10.44 % YoY.

arrow icon

What is Repligen Corp (RGEN)'s earnings per share (EPS) for the last quarter?

Repligen Corp. EPS for the last quarter amounts to 0.10 USD, increased 66.67 % YoY.

arrow icon

What changes have occurred in the market's expectations for Repligen Corp (RGEN)'s fundamentals?

The market is revising Upward the revenue expectations for Repligen Corporation (RGEN) for FY2025, with the revenue forecasts being adjusted by 1.37% over the past three months. During the same period, the stock price has changed by -7.82%.
arrow icon

How many employees does Repligen Corp (RGEN). have?

Repligen Corp (RGEN) has 1783 emplpoyees as of June 13 2025.

arrow icon

What is Repligen Corp (RGEN) market cap?

Today RGEN has the market capitalization of 7.38B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free